Planned phase II trial of RG 7624 (NI-1401) in patients with autoimmune disorders

Trial Profile

Planned phase II trial of RG 7624 (NI-1401) in patients with autoimmune disorders

Planning
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Afasevikumab (Primary)
  • Indications Autoimmune disorders
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 22 Sep 2014 New trial record
    • 05 Aug 2014 This trial is expected to be initiated in early 2015, according to a Novimmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top